Denali Therapeutics (DNLI) Other Working Capital Changes (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Other Working Capital Changes data on file, last reported at -$379000.0 in Q4 2023.

• On a quarterly basis, Other Working Capital Changes fell 101.21% year-over-year to -$379000.0 in Q4 2023; TTM through Dec 2023 was -$379000.0, a N/A change from a year earlier, with the FY2023 full-year figure at -$379000.0, changed N/A from the prior year.
• Other Working Capital Changes for Q4 2023 stood at -$379000.0, down from $31.3 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for DNLI reached as high as $28.6 million in Q1 2025 and fell as low as -$25.0 million in Q2 2025.
• Historically, Other Working Capital Changes has averaged $715588.2 across 5 years, with a median of -$87000.0 in 2023.
• Across the five-year window, Other Working Capital Changes surged 871.12% in 2021 and sank 2980.8% in 2022, its largest moves.
• Year by year, Other Working Capital Changes stood at -$2.8 million in 2019, then jumped by 52.34% to -$1.3 million in 2020, then jumped by 871.12% to $10.3 million in 2021, then soared by 204.41% to $31.3 million in 2022, then plunged by 101.21% to -$379000.0 in 2023.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were -$379000.0 in Q4 2023, $31.3 million in Q4 2022, and -$3.4 million in Q3 2022.